Pediatr. praxi. 2025;26(2):104-110 | DOI: 10.36290/ped.2025.020

Melanoma in children and adolescents

doc. MUDr. Jarmila Čelakovská, Ph.D., MUDr. Veronika Wertzová, Ph.D.
Klinika nemocí kožních a pohlavních, Fakultní nemocnice Hradec Králové, Lékařská fakulta v Hradci Králové, Univerzita Karlova

Melanoma in children is relatively rare, making it difficult to determine prognostic factors, biological behavior, and efficacy of therapy in the pediatric population. The article presents the results of studies and a review of the literature regarding the incidence of melanoma in patients younger than 21 years. The characteristic features of melanoma in children, risk factors, histological and immunohistochemical features, and treatment options are discussed. Studies suggest that careful analysis of histologi­cal and immunohistochemical features should allow for the correct diagnosis in most cases of melanoma in children. Although patients with melanoma in childhood have a higher chance of survival than adults, many children develop metastases, especially when melanoma is diagnosed after puberty. Although melanoma is a rare childhood disease, it is the most common type of skin cancer in young people. With its increa­sing incidence, it is important to consider this disease; melanoma in children is often overlooked and diagnosis is delayed.

Keywords: melanoma, childhood, Spitz nevus, heredity, UV radiation.

Accepted: May 2, 2025; Published: May 6, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čelakovská J, Wertzová V. Melanoma in children and adolescents. Pediatr. praxi. 2025;26(2):104-110. doi: 10.36290/ped.2025.020.
Download citation
PDF will be unlocked 6.5.2026

References

  1. Cancer Today. Available from: https://gco.iarc.fr/today/online-analysis-table (Accessed March 26, 2021).
  2. Ferrari A, Brecht IB, Gatta G, et al. Defining and Listing Very Rare Cancers of Paediatric Age: Consensus of the Joint Action on Rare Cancers in Cooperation With the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer. 2019;110:120-126. doi:10.1016/j.ejca.2018.12.031.  Go to original source... Go to PubMed...
  3. Pasierbska E. Melanoma in children and adolescents. Forum Dermatologicum. 2025;11(1):19-24. doi: 10.5603/fd.104140. Go to original source...
  4. Stefanaki C, Chardalias L, Soura E, et al. Paediatric melanoma. J Eur Acad Dermatol Venereol. 2017;31(10):1604-1615. doi: 10.1111/jdv.14299. Go to original source... Go to PubMed...
  5. Bajčiová V. Maligní melanom u dětí a adolescentů. Onkologie. 2013;7(2):69-73.
  6. Ipenburg NA, Lo SN, Vilain RE, et al. The prognostic value of tumor mitotic rate in children and adolescents with cutaneous melanoma: A retrospective cohort study. J Am Acad Dermatol. 2020;82(4):910-919. doi: 10.1016/j.jaad.2019.10.065, indexed in Pubmed: 31682859. Go to original source... Go to PubMed...
  7. Ferrari A, Lopez Almaraz R, Reguerre Y, et al. Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatr Blood Cancer. 2021; 68 Suppl 4: e28992. doi: 10.1002/pbc.28992 indexed in Pubmed: 34174159. Go to original source... Go to PubMed...
  8. Paradela S, Fonseca E, Pita-Fernández S, et al. Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients. Cancer. 2010;116(18):4334-4344. doi: 10.1002/cncr.25222. PMID: 20549825. Go to original source... Go to PubMed...
  9. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115(3):649-654. doi: 10.1542/peds.2004-0471. PMID: 15741367. Go to original source... Go to PubMed...
  10. Valcayo-Peñalba A, Sánchez-Yus E. El melanoma maligno en menores de quince años (MM sub-15). Un problema poco y mal estudiado. Actas Dermosifiliogr. 77.12. 1986: 717-723.
  11. Sander B, Karlsson P, Rosdahl I, et al. Cutaneous malignant melanoma in Swedish children and teenagers 1973-1992: a clinico-pathological study of 130 cases. Int J Cancer. 1999;80(5): 646-651. doi: 10.1002/(sici)1097-0215(19990301)80:5<646:aid-ijc2>3.0.co;2-h. PMID: 10048960. Go to original source...
  12. Mones JM, Ackerman AB. Melanomas in prepubescent children: review comprehensively, critique historically, criteria diagnostically, and course biologically. Am J Dermatopathol. 2003;25(3):223-238. doi: 10.1097/00000372-200306000-00007. PMID: 12775985. Go to original source... Go to PubMed...
  13. Spitz S. Melanomas of childhood. Am J Pathol. 1948;24: 591-609. Go to original source...
  14. Reed RJ, Ichinose H, Clark WH, et al. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol. 1975;2:119-147.
  15. Ruiz-Maldonado R, Orozco-Covarrubias ML. Malignant melanoma in children. A review. Arch Dermatol. 1997;133(3): 363-371. Erratum in: Arch Dermatol 1997;133(7):833. PMID: 9080898. Go to original source...
  16. 17. Sargen MR, Barnhill RL, Elder DE, et al. Evaluation and surgical management of pediatric cutaneous melanoma and atypical spitz and non-spitz melanocytic tumors (melanocytomas): A report from children's oncology group. J Clin Oncol. 2024: JCO2401154. doi: 10.1200/JCO.24.01154. Go to original source... Go to PubMed...
  17. 18. Sosnowska-Sienkiewicz P, Januszkiewicz-Lewandowska D, Calik J, et al. Nevi and melanoma in children: What to do in daily medical practice: Encyclopedia for pediatricians and family doctors. Diagnostics (Basel). 2024;14(18), doi: 10.3390/diagnostics14182004. Go to original source... Go to PubMed...
  18. 19. Scoville SD, Stanek JR, Rinehardt H, et al. Comparison of outcomes between surveillance ultrasound and completion lymph node dissection in children and adolescents with sentinel lymph node-positive cutaneous melanoma. Ann Surg. 2024;279(3):536-541. Go to original source... Go to PubMed...
  19. 20. Wu YP, Tercyak KP, Wankier AP, et al. Moderating influences on parents' fatalistic beliefs about cancer and their association with sun safety behaviors among children of melanoma survivors: Implications for treatment. J Health Psychol. 2024;29(5):481-491. Go to original source... Go to PubMed...
  20. 21. Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 2004;14(4):251-255. doi: 10.1097/01.cmr.0000131014.79262.bf. PMID: 15305154. Go to original source... Go to PubMed...
  21. 22. Leech SN, Bell H, Leonard N, et al. Neonatal giant congenital nevi with proliferative nodules: a clinicopathologic study and literature review of neonatal melanoma. Arch Dermatol. 2004;140(1):83-88. doi: 10.1001/archderm.140.1.83. PMID: 14732664. Go to original source... Go to PubMed...
  22. 23. Paradela S, Fernández-Torres R, Fonseca E. Controversias en el nevus congénito [Controversial issues in congenital nevi]. Actas Dermosifiliogr. 2009;100(7):548-561. Spanish. PMID: 19715640. Go to original source...
  23. 24. Pampena R, Piccolo V, Muscianese M, et al. Melanoma in children: A systematic review and individual patient meta-analysis. J Eur Acad Dermatol Venereol. 2023;37(9):1758-1776. doi: 10.1111/jdv.19220. Go to original source... Go to PubMed...
  24. 25. Jahnke MN, O'Haver J, Gupta D, et al. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations. Pediatrics. 2021;148(6):e2021051536. doi: 10.1542/peds.2021-051536. PMID: 34845496. Go to original source... Go to PubMed...
  25. 26. Barnhill RL. Pathology of melanocytic nevi and malignant melanoma. Springer Science & Business Media, 2013. Go to original source...
  26. 27. Liebmann A, Admard J, Armeanu-Ebinger S, et al. UV-radiation and MC1R germline mutations are risk factors for the development of conventional and spitzoid melanomas in children and adolescents. EBioMedicine. 2023;96:104797. doi: 10.1016/j.ebiom.2023.104797. Epub 2023 Sep 14. PMID: 37716236; PMCID: PMC10511785. Go to original source... Go to PubMed...
  27. 28. Kefford RF, Newton Bishop JA, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999;17(10):3245-3251. doi: 10.1200/JCO.1999.17.10.3245. PMID: 10506626. Go to original source... Go to PubMed...
  28. 29. Nakata K, Charvat H. International variations in carcinoma and melanoma incidence in children and adolescents. Jpn J Clin Oncol. 2022;52(12):1452-1454. doi: 10.1093/jjco/hyac179. Go to original source... Go to PubMed...
  29. 30. McKenna DB, Doherty VR, McLaren KM, et al. Malignant melanoma and lymphoproliferative malignancy: is there a shared aetiology? Br J Dermatol. 2000;143(1):171-173. doi: 10.1046/j.1365-2133.2000.03610.x. PMID: 10886155. Go to original source... Go to PubMed...
  30. 31. Paradela S, Fonseca E, Pita S, et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J Cutan Pathol. 2009;36(7):740-752. doi: 10.1111/j.1600-0560.2008.01153.x. Epub 2008 Nov 5. PMID: 19032380. Go to original source... Go to PubMed...
  31. 32. Larrosa C, Torrelo A, Madero L, et al. Melanoma in prepuberal children: Diagnostic and therapeutic challenges. An Pediatr (Engl Ed). 2022;96(4):352-357. doi: 10.1016/j.anpede.2021.01.010. Go to original source... Go to PubMed...
  32. 33. Fu YJ, Morota N, Nakagawa A, et al. Neurocutaneous melanosis: surgical pathological features of an apparently hamartomatous lesion in the amygdala. J Neurosurg Pediatr. 2010;6(1):82-86. doi: 10.3171/2010.3.PEDS1025. PMID: 20593992. Go to original source... Go to PubMed...
  33. 34. Gargallo P, Yáñez Y, Segura V, et al. Li-Fraumeni syndrome heterogeneity. Clin Transl Oncol. 2020;22(7):978-988. Go to original source... Go to PubMed...
  34. 35. Helgadottir H. Melanoma susceptibility genes in paediatric melanoma and differences in children or adolescents and sporadic or familial cases. J Eur Acad Dermatol Venereol. 2022;36(2):167-168. doi: 10.1111/jdv.17879, indexed in Pub­med: 35037305. Go to original source... Go to PubMed...
  35. 36. Piccolo V, Moscarella E, Lallas A, et al. MELTUMP: how to manage these lesions in the clinical routine. G Ital Dermatol Venereol. 2017;152(3):266-269. doi: 10.23736/S0392-0488.17.05569-9. Epub 2017 Feb 14. PMID: 28195450. Go to original source... Go to PubMed...
  36. 37. Herron MD, Vanderhooft SL, Smock K, et al. Proliferative nodules in congenital melanocytic nevi: a clinicopathologic and immunohistochemical analysis. Am J Surg Pathol. 2004;28(8):1017-1025. doi: 10.1097/01.pas.0000126785.61609.6e. PMID: 15252307. Go to original source... Go to PubMed...
  37. 38. Ravid JM, Esteves JA. Malignant melanoma of the nose and paranasal sinuses and juvenile melanoma of the nose. Arch Otolaryngol. 1960;72:431-444. doi: 10.1001/archotol.1960.00740010441002. PMID: 13739890. Go to original source... Go to PubMed...
  38. 39. Hanchard B, Salmon B. Primary malignant melanoma of the maxillary gingiva in a 4-year-old girl. West Indian Med J. 1985;34(4):278-281. PMID: 4090476.
  39. 40. Patton EE, Mueller KL, Adams DJ, et al. Melanoma models for the next generation of therapies. Cancer Cell. 2021;39(5):610-631. doi: 10.1016/j.ccell.2021.01.011. Epub 2021 Feb 4. PMID: 33545064; PMCID: PMC8378471. Go to original source... Go to PubMed...
  40. 41. Urso C. Spitz Tumors and Melanoma in the Genomic Age: A Retrospective Look at Ackerman's Conundrum. Cancers (Basel). 2023;15(24):5834. doi: 10.3390/cancers15245834. PMID: 38136379; PMCID: PMC10741987. Go to original source... Go to PubMed...
  41. 42. Sandru A, Bordea CI, Voinea SC, et al. Actualităţi în tratamentul chirurgical al melanomului malign cutanat [Latest approaches in the surgical treatment of cutaneous malignant melanoma]. Chirurgia (Bucur). 2011;106(3):301-308.
  42. 43. Pavlick AC. Chemotherapy approaches to melanoma. Dermatol Clin. 2002;20(4):709-712. doi: 10.1016/s0733-8635(02)00033-5. PMID: 12380057. Go to original source... Go to PubMed...
  43. 44. Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opin Investig Drugs. 2012;21(4):557-568. doi: 10.1517/13543784.2012.665872. Epub 2012 Mar 7. PMID: 22394203. Go to original source... Go to PubMed...
  44. 45. Guo X, Huang S, Zhang Y, et al. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway. J Nat Med. 2024;78(2):342-354. doi: 10.1007/s11418-023-01769-9. Epub 2024 Feb 7. PMID: 38324123. Go to original source... Go to PubMed...
  45. 46. Holzgruber J, Martins C, Kulcsar Z, et al. Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. Nat Commun. 2024;15(1):7165. doi: 10.1038/s41467-024-51496-2. PMID: 39187481; PMCID: PMC11347607. Go to original source... Go to PubMed...
  46. 47. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14(17):5610-5618. doi: 10.1158/1078-0432.CCR-08-0116. PMID: 18765555; PMCID: PMC2656367. Go to original source... Go to PubMed...
  47. 48. Hogg D, Monzon JG, Ernst S, et al. Canadian cohort expanded-access program of nivolumab plus ipilimumab in advanced melanoma. Curr Oncol. 2020;27(4):204-214. doi: 10.3747/co.27.5985. Epub 2020 Aug 1. PMID: 32905202; PMCID: PMC7467793. Go to original source... Go to PubMed...
  48. 49. Purim KSM, DE-PrÁ MV, Bahr DC, et al. Survival analysis of children and adolescents with melanoma. Rev Col Bras Cir. 2020;47:e20202460. English, Portuguese. doi: 10.1590/0100-6991e-20202460. PMID: 33263650. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.